{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:37:58Z","timestamp":1772120278141,"version":"3.50.1"},"reference-count":106,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100009573","name":"Universidad Nacional de Rosario","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009573","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.bcp.2020.113909","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T22:32:15Z","timestamp":1584052335000},"page":"113909","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Achievements and challenges in the use of metronomics for the treatment of breast cancer"],"prefix":"10.1016","volume":"175","author":[{"given":"O. Graciela","family":"Scharovsky","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Rico","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leandro E.","family":"Mainetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herman A.","family":"Perroud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviana R.","family":"Rozados","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2020.113909_b0005","first-page":"394","article-title":"Global Cancer Statistics 2018: GLOBOCAN estimates of Incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bcp.2020.113909_b0010","unstructured":"Breastcancer.org. https:\/\/www.breastcancer.org \u203a symptoms \u203a understand_bc \u203a statistics. 2019."},{"key":"10.1016\/j.bcp.2020.113909_b0015","unstructured":"IARC estimates for Argentina in 2018. https:\/\/www.argentina.gob.ar\/salud\/instituto-nacional-del-cancer\/estadisticas\/incidencia. 2018."},{"key":"10.1016\/j.bcp.2020.113909_b0020","unstructured":"American Cancer Society https:\/\/www.cancer.org\/cancer\/breast-cancer\/understanding-a-breast-cancer-diagnosis\/breast-cancer-survival-rates.html. 2019."},{"key":"10.1016\/j.bcp.2020.113909_b0025","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nrc1650","article-title":"Repopulation of cancer cells during therapy: an important cause of treatment failure","volume":"5","author":"Kim","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2020.113909_b0030","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1172\/JCI9872","article-title":"Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice","volume":"105","author":"Hanahan","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2020.113909_b0035","first-page":"1878","article-title":"Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer","volume":"60","author":"Browder","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2020.113909_b0040","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1172\/JCI8829","article-title":"Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity","volume":"105","author":"Klement","year":"2000","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2020.113909_b0045","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrc1369","article-title":"The anti-angiogenic basis of metronomic chemotherapy","volume":"4","author":"Kerbel","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bcp.2020.113909_b0050","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3747\/co.v16i2.420","article-title":"Metronomic chemotherapy. Changing the paradigm that more is better","volume":"16","author":"Scharovsky","year":"2009","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.bcp.2020.113909_b0055","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4103\/0019-509X.117027","article-title":"Metronomic therapy: chemotherapy revisited","volume":"50","author":"Noronha","year":"2013","journal-title":"Indian J. Cancer"},{"key":"10.1016\/j.bcp.2020.113909_b0060","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.1016\/j.ejca.2013.06.038","article-title":"Low-dose metronomic chemotherapy: a systematic literature analysis","volume":"49","author":"Lien","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bcp.2020.113909_b0065","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.trecan.2017.03.011","article-title":"Metronomic Chemotherapy: Direct Targeting of Cancer Cells after all?","volume":"3","author":"Andr\u00e9","year":"2017","journal-title":"Trends Cancer"},{"key":"10.1016\/j.bcp.2020.113909_b0070","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.canlet.2014.12.039","article-title":"Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance","volume":"358","author":"Kareva","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2020.113909_b0075","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10637-016-0408-x","article-title":"Current achievements and future perspectives of metronomic chemotherapy","volume":"35","author":"Romiti","year":"2017","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.bcp.2020.113909_b0080","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.canlet.2018.06.002","article-title":"Does metronomic chemotherapy induce tumor angiogenic dormancy? A review of available preclinical and clinical data","volume":"432","author":"Natale","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2020.113909_b0085","unstructured":"National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology. Breast Cancer (Version 1.2019). National Comprehensive Cancer Network, 2019."},{"key":"10.1016\/j.bcp.2020.113909_b0090","first-page":"1","article-title":"Metronomic chemotherapy for children in low and middle incomes countries: survey of current practices and opinions of pediatric oncologists","volume":"5","author":"Revon-Rivi\u00e8re","year":"2019","journal-title":"J. Glob Oncol."},{"key":"10.1016\/j.bcp.2020.113909_b0095","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1182\/blood-2005-11-4570","article-title":"Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy","volume":"108","author":"Mancuso","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2020.113909_b0100","doi-asserted-by":"crossref","first-page":"7652","DOI":"10.1158\/1078-0432.CCR-09-1493","article-title":"Predictive potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab","volume":"15","author":"Calleri","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2020.113909_b0105","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.clbc.2012.03.008","article-title":"Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity","volume":"12","author":"Montagna","year":"2012","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.bcp.2020.113909_b0110","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/annonc\/mdf013","article-title":"Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels","volume":"13","author":"Colleoni","year":"2002","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2020.113909_b0115","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1093\/annonc\/mdj066","article-title":"Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects","volume":"17","author":"Colleoni","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bcp.2020.113909_b0120","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2217\/fon.12.196","article-title":"Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients","volume":"9","author":"Perroud","year":"2013","journal-title":"Future Oncol."},{"key":"10.1016\/j.bcp.2020.113909_b0125","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4161\/cbt.7.1.5337","article-title":"Circulating biomarkers of bevacizumab activity in patients with breast cancer","volume":"7","author":"Denduluri","year":"2008","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.bcp.2020.113909_b0130","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4103\/0019-509X.117031","article-title":"Association between baseline VEGF\/sVEGFR-2 and VEGF\/TSP-1 ratios and response to metronomic chemotherapy using cyclophosphamide and celecoxib in patients with advanced breast cancer","volume":"50","author":"Perroud","year":"2013","journal-title":"Indian J. Cancer"},{"key":"10.1016\/j.bcp.2020.113909_b0135","doi-asserted-by":"crossref","first-page":"12917","DOI":"10.1073\/pnas.2135406100","article-title":"Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy","volume":"100","author":"Bocci","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bcp.2020.113909_b0140","doi-asserted-by":"crossref","first-page":"662","DOI":"10.18632\/oncotarget.200","article-title":"Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors","volume":"1","author":"Taraboletti","year":"2010","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2020.113909_b0145","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00262-012-1343-0","article-title":"Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo","volume":"62","author":"Tongu","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bcp.2020.113909_b0150","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bcp.2020.113909_b0155","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s00262-011-1106-3","article-title":"Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome","volume":"61","author":"Ge","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bcp.2020.113909_b0160","article-title":"Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells","volume":"pii","author":"Peereboom","year":"2019","journal-title":"JCI Insight 4"},{"key":"10.1016\/j.bcp.2020.113909_b0165","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.21037\/jtd.2017.08.68","article-title":"Anti-cancer activity of dose-fractioned mPE +\/- bevacizumab regimen is paralleled by immune-modulation in advanced squamous NSLC patients","volume":"9","author":"Pastina","year":"2017","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.bcp.2020.113909_b0170","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.canlet.2017.02.005","article-title":"The potential clinical promise of \u2018multimodality\u2019 metronomic chemotherapy revealed by preclinical studies of metastatic disease","volume":"400","author":"Kerbel","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2020.113909_b0175","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/1535-7163.MCT-11-0659","article-title":"Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis","volume":"11","author":"Francia","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2020.113909_b0180","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3332\/ecancer.2014.485","article-title":"The Repurposing Drugs in Oncology (ReDO) Project","volume":"8","author":"Pantziarka","year":"2014","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.bcp.2020.113909_b0185","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2217\/fon.14.244","article-title":"Repurposing drugs in your medicine cabinet: untapped opportunities for cancer therapy?","volume":"11","author":"Pantziarka","year":"2015","journal-title":"Future Oncol."},{"key":"10.1016\/j.bcp.2020.113909_b0190","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1016\/S1470-2045(13)70056-1","article-title":"Has the time come for metronomics in low-income and middle-income countries?","volume":"14","author":"Andr\u00e9","year":"2013","journal-title":"Lancet Oncol."},{"issue":"16","key":"10.1016\/j.bcp.2020.113909_b0195","doi-asserted-by":"crossref","first-page":"7045","DOI":"10.1158\/0008-5472.CAN-05-0765","article-title":"Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy","volume":"65","author":"Shaked","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2020.113909_b0200","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3109\/07357900902744510","article-title":"Low-dose metronomic paclitaxel chemotherapy suppresses breast tumors and metastases in mice","volume":"28","author":"Jiang","year":"2010","journal-title":"Cancer Invest."},{"key":"10.1016\/j.bcp.2020.113909_b0205","first-page":"2731","article-title":"Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water","volume":"62","author":"Man","year":"2002","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bcp.2020.113909_b0210","first-page":"221","article-title":"Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts","volume":"8","author":"Klement","year":"2002","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bcp.2020.113909_b0215","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1158\/0008-5472.CAN-05-2598","article-title":"Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia","volume":"66","author":"Emmenegger","year":"2006","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.bcp.2020.113909_b0220","doi-asserted-by":"crossref","first-page":"3386","DOI":"10.1158\/0008-5472.CAN-05-4411","article-title":"Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy","volume":"66","author":"Munoz","year":"2006","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.bcp.2020.113909_b0225","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1158\/1535-7163.MCT-09-0583","article-title":"Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models","volume":"8","author":"Daenen","year":"2009","journal-title":"Mol. Cancer. Ther"},{"issue":"20","key":"10.1016\/j.bcp.2020.113909_b0230","doi-asserted-by":"crossref","first-page":"6358","DOI":"10.1158\/1078-0432.CCR-09-0931","article-title":"Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts","volume":"15","author":"Francia","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2020.113909_b0235","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00432-010-0869-9","article-title":"Antitumoral and antimetastatic effects of metronomic chemotherapy with cyclophosphamide combined with celecoxib on murine mammary adenocarcinomas","volume":"137","author":"Mainetti","year":"2011","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.bcp.2020.113909_b0240","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1093\/annonc\/mdt164","article-title":"Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas","volume":"24","author":"Mainetti","year":"2013","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.bcp.2020.113909_b0245","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1002\/ijc.27977","article-title":"Antitumor effects of combining metronomic chemotherapy with the antivascular action of ultrasound stimulated microbubbles","volume":"132","author":"Todorova","year":"2013","journal-title":"Int J Cancer"},{"issue":"20","key":"10.1016\/j.bcp.2020.113909_b0250","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1158\/0008-5472.CAN-16-0136","article-title":"Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy","volume":"76","author":"Shaked","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2020.113909_b0255","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: Similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2020.113909_b0260","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/bjc.2016.429","article-title":"Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth","volume":"116","author":"Parra","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2020.113909_b0265","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1158\/1535-7163.MCT-16-0263","article-title":"Antitumor Synergism and Enhanced Survival with a Tumor Vasculature-Targeted Enzyme Prodrug System, Rapamycin, and Cyclophosphamide","volume":"16","author":"Krais","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2020.113909_b0270","doi-asserted-by":"crossref","unstructured":"Guercetti J, Mainetti LE, Grillo MC, Del Gi\u00fadice A, Baglioni MV, C\u00e1ceres JM, et al. Metronomic chemotherapy with cyclophosphamide (Cy) and the repositioned drug losartan (Los) for the treatment of M-234p triple negative murine mammary adenocarcinoma. In: Proc Annu Meet Am Assoc Cancer Res 50:1, 2018.","DOI":"10.1158\/1538-7445.AM2018-3"},{"issue":"10","key":"10.1016\/j.bcp.2020.113909_b0275","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/s41416-018-0076-z","article-title":"Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma","volume":"118","author":"Orecchioni","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2020.113909_b0280","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.biomaterials.2018.08.007","article-title":"Metronomic oral doxorubicin in combination of Chk1 inhibitor MK-8776 for p53-deficient breast cancer treatment","volume":"182","author":"Chung","year":"2018","journal-title":"Biomaterials"},{"key":"10.1016\/j.bcp.2020.113909_b0285","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.bcp.2018.08.041","article-title":"Methylglyoxal at metronomic doses sensitizes breast cancer cells to doxorubicin and cisplatin causing synergistic induction of programmed cell death and inhibition of stemness","volume":"156","author":"Roy","year":"2018","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.bcp.2020.113909_b0290","first-page":"647","article-title":"Antiangiogenic effect of capecitabine combined with ginsenoside Rg3 on breast cancer in mice","volume":"23","author":"Zhang","year":"2008","journal-title":"Cancer Biother. Radiopharm."},{"issue":"7","key":"10.1016\/j.bcp.2020.113909_b0295","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.4161\/onci.21057","article-title":"Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer","volume":"1","author":"Foy","year":"2012","journal-title":"Oncoimmunology"},{"issue":"Suppl 2","key":"10.1016\/j.bcp.2020.113909_b0300","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.breast.2013.07.011","article-title":"Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis","volume":"22","author":"Kerbel","year":"2013","journal-title":"Breast"},{"issue":"6","key":"10.1016\/j.bcp.2020.113909_b0305","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.ccell.2014.11.005","article-title":"Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth","volume":"26","author":"Srivastava","year":"2014","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.bcp.2020.113909_b0310","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3892\/or.2015.4001","article-title":"The combined use of Camellia sinensis and metronomic zoledronate in 4T1 mouse carcinoma against tumor growth and metastasis\u201c","volume":"34","author":"Luo","year":"2015","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bcp.2020.113909_b0315","doi-asserted-by":"crossref","first-page":"42396","DOI":"10.18632\/oncotarget.6377","article-title":"Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer","volume":"6","author":"Di Desidero","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2020.113909_b0320","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jep.2017.04.007","article-title":"Evaluation of the combined use of metronomic zoledronic acid and Coriolus versicolor in intratibial breast cancer mouse model","volume":"204","author":"Ko","year":"2017","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.bcp.2020.113909_b0325","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.18632\/oncotarget.13760","article-title":"Metformin and propranolol combination prevents cancer progression and metastasis in different breast cancer models","volume":"8","author":"Rico","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2020.113909_b0330","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1200\/JCO.2005.04.5773","article-title":"Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients","volume":"24","author":"Bottini","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2020.113909_b0335","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.breast.2011.02.014","article-title":"Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer","volume":"20","author":"Dellapasqua","year":"2011","journal-title":"Breast"},{"key":"10.1016\/j.bcp.2020.113909_b0340","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.clbc.2015.03.002","article-title":"Phase II study with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel with metronomic cyclophosphamide as a preoperative treatment of triple-negative breast cancer","volume":"15","author":"Cancello","year":"2015","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.bcp.2020.113909_b0345","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1590\/1414-431x20144354","article-title":"Metronomic chemotherapy in the neoadjuvant setting: results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2- locally advanced breast cancer","volume":"48","author":"Petry","year":"2015","journal-title":"Braz. J. Med. Biol. Res."},{"issue":"2","key":"10.1016\/j.bcp.2020.113909_b0350","article-title":"Quimioterapia metron\u00f3mica con ciclofosfamida y metotrexato en pacientes con c\u00e1ncer de mama metast\u00e1sico en progresi\u00f3n","volume":"48","author":"Soriano Garc\u00eda","year":"2009","journal-title":"Revista Cubana de Medicina"},{"key":"10.1016\/j.bcp.2020.113909_b0355","first-page":"134","article-title":"Phase II trial of metronomic chemotherapy as salvage therapy for patients with metastatic breast cancer.\u201c","volume":"20","author":"Salem","year":"2008","journal-title":"J Egypt Natl Canc Inst"},{"key":"10.1016\/j.bcp.2020.113909_b0360","first-page":"529","article-title":"Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma","volume":"32","author":"Gebbia","year":"2012","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bcp.2020.113909_b0365","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/1471-2407-6-225","article-title":"Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer","volume":"6","author":"Orlando","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bcp.2020.113909_b0370","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1179\/joc.2008.20.5.632","article-title":"Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer","volume":"20","author":"Garcia-Saenz","year":"2008","journal-title":"J. Chemother."},{"key":"10.1016\/j.bcp.2020.113909_b0375","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10549-012-2256-5","article-title":"Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics","volume":"136","author":"Mayer","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bcp.2020.113909_b0380","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1524-4741.2012.01278.x","article-title":"Oral metronomic cyclophosphamide and methotrexate plus fulvestrant in advanced breast cancer patients: a mono-institutional case-cohort report","volume":"18","author":"Aurilio","year":"2012","journal-title":"Breast J."},{"key":"10.1016\/j.bcp.2020.113909_b0385","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1200\/JCO.2009.24.0143","volume":"28","author":"Wong","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2020.113909_b0390","doi-asserted-by":"crossref","DOI":"10.4061\/2011\/710292","article-title":"Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer","volume":"2011","author":"Soriano","year":"2011","journal-title":"Int J Breast Cancer"},{"key":"10.1016\/j.bcp.2020.113909_b0395","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2011.06.040","article-title":"Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer","volume":"48","author":"Fedele","year":"2012","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.bcp.2020.113909_b0400","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jnci.2011.12.002","article-title":"Metronomic chemotherapy in metastatic breast cancer: impact on VEGF","volume":"24","author":"El-Arab","year":"2012","journal-title":"J Egypt Natl Canc Inst"},{"key":"10.1016\/j.bcp.2020.113909_b0405","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00280-011-1728-3","article-title":"An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study","volume":"69","author":"Wang","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bcp.2020.113909_b0410","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clbc.2013.09.003","article-title":"Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer","volume":"14","author":"Schwartzberg","year":"2014","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.bcp.2020.113909_b0415","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1200\/JCO.2008.17.4789","article-title":"Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer","volume":"26","author":"Dellapasqua","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2020.113909_b0420","doi-asserted-by":"crossref","first-page":"239","DOI":"10.4137\/BCBCR.S7379","article-title":"Efficacy of bevacizumab-capecitabine in combination for the first-line treatment of metastatic breast cancer","volume":"5","author":"Dyar","year":"2011","journal-title":"Breast Cancer (Auckl)"},{"key":"10.1016\/j.bcp.2020.113909_b0425","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00280-011-1663-3","article-title":"A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer","volume":"69","author":"Saridaki","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bcp.2020.113909_b0430","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/769790","article-title":"Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study","volume":"2014","author":"Cazzaniga","year":"2014","journal-title":"Int J Breast Cancer"},{"key":"10.1016\/j.bcp.2020.113909_b0435","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.3747\/co.19.879","article-title":"Phase ii trial of a metronomic schedule of docetaxel and capecitabine with concurrent celecoxib in patients with prior anthracycline exposure for metastatic breast cancer","volume":"19","author":"Young","year":"2012","journal-title":"Curr Oncol"},{"key":"10.1016\/j.bcp.2020.113909_b0440","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s12282-013-0483-1","article-title":"Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer","volume":"22","author":"Otsuka","year":"2015","journal-title":"Breast Cancer"},{"key":"10.1016\/j.bcp.2020.113909_b0445","first-page":"4569","article-title":"Expression of angiogenic markers in the peripheral blood of patients with advanced breast cancer treated with weekly docetaxel","volume":"32","author":"Korantzis","year":"2012","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bcp.2020.113909_b0450","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s12094-012-0954-4","article-title":"Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients","volume":"15","author":"Manso","year":"2013","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.bcp.2020.113909_b0455","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1179\/joc.2010.22.3.201","article-title":"Oral metronomic chemo-hormonal-therapy of metastatic breast cancer with cyclophosphamide and megestrol acetate","volume":"22","author":"Licchetta","year":"2012","journal-title":"J. Chemother."},{"key":"10.1016\/j.bcp.2020.113909_b0460","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3816\/CBC.2010.n.039","article-title":"Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer","volume":"10","author":"Addeo","year":"2010","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.bcp.2020.113909_b0465","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.breast.2009.10.003","article-title":"Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: a mono-institutional case-series report","volume":"19","author":"Munzone","year":"2010","journal-title":"Breast"},{"key":"10.1016\/j.bcp.2020.113909_b0470","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00280-012-1945-4","article-title":"Protracted low dose of oral vinorelbine and temozolomide with whole-brain radiotherapy in the treatment for breast cancer patients with brain metastases","volume":"70","author":"Addeo","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.bcp.2020.113909_b0475","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/BF00665790","article-title":"Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancer","volume":"34","author":"Bontenbal","year":"1995","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bcp.2020.113909_b0480","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1200\/JCO.1994.12.5.986","article-title":"Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer","volume":"12","author":"Martin","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2020.113909_b0485","article-title":"Efficacy of oral Etoposide in pretreated metastatic breast cancer: a multicenter phase 2 study","volume":"94","author":"Yuan","year":"2012","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bcp.2020.113909_b0490","first-page":"284","article-title":"Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study","volume":"3","author":"Nasr","year":"2015","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.bcp.2020.113909_b0495","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood-2005-04-1422","article-title":"Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity","volume":"106","author":"Shaked","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2020.113909_b0500","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nrclinonc.2016.64","article-title":"Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect","volume":"13","author":"Bocci","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bcp.2020.113909_b0505","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s10637-013-9974-3","article-title":"Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy","volume":"32","author":"Chow","year":"2014","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.bcp.2020.113909_b0510","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.canlet.2017.02.027","article-title":"Resistance to metronomic chemotherapy and ways to overcome it","volume":"400","author":"Riesco-Martinez","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2020.113909_b0515","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2020.113909_b0520","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s10549-016-3863-3","article-title":"Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22\u201300","volume":"158","author":"Pruneri","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.bcp.2020.113909_b0525","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1186\/s12885-016-2823-y","volume":"16","author":"Rochlitz","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bcp.2020.113909_b0530","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s12325-018-0844-4","article-title":"Pan-European Expert Meeting on the use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project","volume":"36","author":"Cazzaniga","year":"2019","journal-title":"Adv Ther"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220301374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220301374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:16:51Z","timestamp":1757769411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295220301374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":106,"alternative-id":["S0006295220301374"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2020.113909","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737573218.793581190","asserted-by":"object"}]},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Achievements and challenges in the use of metronomics for the treatment of breast cancer","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2020.113909","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113909"}}